Abbott India Share Price: 3.7% CAGR in 3 Years as the Mumbai Based Drug Maker Compares With Sun Pharma, Torrent Pharma and Cipla
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Abbott India Share Price: 3.7% CAGR in 3 Years as the Mumbai Based Drug Maker Compares With Sun Pharma, Torrent Pharma and Cipla
Abbott India previous close Rs 25,980. 3-year CAGR 3.7%. Up 1.1x since 16 Nov 2023. ROE 38.71%. Market cap Rs 54,950 crore.
Quick Answer
The Abbott India share price closed at Rs 25,980 on 16 November 2026, a compounded annual return of 3.7% over three years. That compares with Sun Pharma at 16.2%, Torrent Pharma at 32.0% and Cipla at 4.1%. The company has a market cap of Rs 54,950 crore and a P/E of 33.25 against an industry P/E of 51.51.
The Abbott India share price closed at Rs 25,980 on 16 November 2026 and has compounded at 3.7% a year over three years. Abbott India, based in Mumbai, sells branded medicines across digestive health, women’s health, neurology and other therapies, and is part of the global Abbott group.
This article places that return beside Sun Pharma, Torrent Pharma and Cipla. We calculate the three-year CAGR for all four and set the results next to market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Abbott India Share Price Returned in 3 Years?
The Abbott India stock closed at Rs 23,293.55 on 16 November 2023 and at Rs 25,980.00 on 16 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.12 lakh, which is a CAGR of 3.7%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Abbott India can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
A price of over Rs 25,000 makes the share a high value stock, and a steady return on that base is a different story from a quick return on a low priced one. The Abbott India share price has also come with a dividend yield of 2.54%, which a price-only CAGR leaves out.
Abbott India vs Sun Pharma, Torrent Pharma and Cipla: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 16 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 16 November 2026.
| Company | Close on 16 Nov 2023 | Previous close (16 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Torrent Pharma | Rs 2,039.55 | Rs 4,691.20 | 2.3x | 32.0% |
| Sun Pharma | Rs 1,189.55 | Rs 1,867.50 | 1.6x | 16.2% |
| Cipla | Rs 1,234.80 | Rs 1,394.50 | 1.1x | 4.1% |
| Abbott India | Rs 23,293.55 | Rs 25,980.00 | 1.1x | 3.7% |
The Abbott India stock ranks fourth of the four at 3.7%. The companies ahead are Torrent Pharma (32.0%), Sun Pharma (16.2%) and Cipla (4.1%). By market cap the company ranks fourth of the four at Rs 54,950 crore. Sun Pharma is the largest of the four by market cap, and Abbott India is the smallest, so the comparison shows how a focused brand company sits beside larger drug makers.
Look at the Abbott India share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Sun Pharma | Rs 4,54,914 crore | 41.41 | 40.71 | 13.79% | 0.04 |
| Torrent Pharma | Rs 1,79,494 crore | 85.52 | 40.55 | 11.42% | 0.77 |
| Cipla | Rs 1,12,620 crore | 39.47 | 40.65 | 8.18% | 0.02 |
| Abbott India | Rs 54,950 crore | 33.25 | 51.51 | 38.71% | 0.04 |
By market cap, Sun Pharma is the largest of the group at Rs 4,54,914 crore, while the Abbott India stock stands at Rs 54,950 crore, about 12% of that size. On earnings, Abbott India shares trade at a P/E of 33.25 against an industry P/E of 51.51, a discount of about 35% to the sector, which leaves room if earnings keep growing. Peer multiples are Sun Pharma at 41.41, Torrent Pharma at 85.52 and Cipla at 39.47.
Return on equity is 38.71% for the Abbott India stock, which ranks first among the four, and debt to equity stands at 0.04. Trailing EPS is Rs 777.82. Abbott India trades at a P/E of 33.25 against an industry P/E of 51.51, a lower multiple than the sector. Its ROE is the highest in the group, which is the other half of the valuation picture.
What Is Driving the Abbott India Stock?
Abbott India sells established brands that doctors prescribe for long term conditions, backed by a strong sales network. The company depends on its brand portfolio rather than on a large product pipeline.
The company earns an ROE of 38.71%, which is the highest in the group, and carries a debt to equity of just 0.04. Its P/E of 33.25 sits below the industry P/E of 51.51.
Investors who follow the Abbott India share price usually track growth in the leading brands, new launches from the parent group, operating margin and the dividend declared each year.
How the Established Players Stack Up
Sun Pharma is a Mumbai-based drug maker and the largest pharma company in the group by market cap. It compounded at 16.2% a year, on a market cap of Rs 4,54,914 crore and an ROE of 13.79%.
Torrent Pharma is an Ahmedabad-based drug maker with a strong presence in chronic therapies in India. It compounded at 32.0% a year, on a market cap of Rs 1,79,494 crore and an ROE of 11.42%.
Cipla is a Mumbai-based drug maker known for respiratory and other therapies. It compounded at 4.1% a year, on a market cap of Rs 1,12,620 crore and an ROE of 8.18%.
What Should Investors Track Next?
Three things are worth watching on the Abbott India share price. First, sales growth in its leading brands. Second, operating margin in the next quarterly result. Third, the dividend declared each year.
At a P/E of 33.25 the stock trades below the industry P/E of 51.51, which leaves room if earnings keep growing. Drug pricing rules can affect margins, so follow each result closely.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Abbott India stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Abbott India share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Abbott India share price and compare pharma stocks live.
A High ROE Drug Maker Beside Three Larger Peers
The Abbott India share price compounded at 3.7% a year over three years, against 32.0% for Torrent Pharma, 16.2% for Sun Pharma and 4.1% for Cipla. Its ROE of 38.71% is the highest of the four.
Torrent Pharma brings the fastest return, Abbott India brings the highest ROE and the lowest P/E, and Sun Pharma brings the largest market cap. The right pick depends on which strength matters most to you.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Abbott India share price today?
Ans. Abbott India closed at Rs 25,980 on 16 November 2026, according to NSE data. It has a market cap of Rs 54,950 crore and a P/E of 33.25. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Abbott India stock?
Ans. Abbott India delivered a price CAGR of 3.7% over three years, moving from Rs 23,293.55 on 16 November 2023 to Rs 25,980.00 on 16 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Abbott India better than Cipla?
Ans. Cipla delivered a slightly higher three-year CAGR at 4.1% against 3.7% for Abbott India, and has a larger market cap at Rs 1,12,620 crore. Abbott India has the higher ROE at 38.71% against 8.18% and a lower P/E of 33.25 against 39.47. The better choice depends on whether you prefer a higher return on equity or a larger company.
What does Abbott India do?
Ans. Abbott India Limited is a Mumbai-based pharmaceutical company that markets branded medicines in India and is part of the global Abbott group.
Is the Abbott India stock debt free?
Ans. The debt to equity ratio of the Abbott India stock is 0.04 and its return on equity is 38.71%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Abbott India expensive compared with the industry?
Ans. Abbott India trades at a P/E of 33.25 against an industry P/E of 51.51. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Torrent Pharma delivered the highest three-year CAGR at 32.0%, followed by Sun Pharma at 16.2%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.